Drug intelligence / Profile preview

tetrahydrocannabivarin

Development stage
Phase 2
Lead developer
InMed Pharmaceuticals
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Inhalation, Oral, Sublingual
01

Overview

Tetrahydrocannabivarin (THCV) is a naturally occurring cannabinoid found in the Cannabis sativa plant. It is a propyl analogue of tetrahydrocannabinol (Δ9-THC), differing by the length of its alkyl side chain, and is considered a major phytocannabinoid present in some cannabis strains. Unlike THC, THCV typically lacks psychoactive effects at standard doses and may even counteract some of THC’s intoxicating properties. Mechanistically, THCV acts as an antagonist at the Cannabinoid 1 receptor (CB1) and as a partial agonist at the Cannabinoid 2 receptor (CB2). It also exhibits agonist activity at GPR55 and l-alpha-lysophosphatidylinositol receptors, with additional evidence suggesting activation of 5HT1A serotonin receptors. Preclinical studies indicate that THCV can suppress appetite, improve glycemic control, enhance insulin sensitivity, reduce lipid accumulation, and provide neuroprotection. These properties make it a candidate for managing metabolic disorders such as obesity and type 2 diabetes; it has also been investigated for potential benefits in conditions like seizures and schizophrenia. However, purified or isolated THCV is not approved for any medical use nor available as a marketed pharmaceutical product[2][4][6][8].

Other names
tetrahydrocannabivarin
02

Targets

GPR55 (G protein-coupled receptor 55)CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on tetrahydrocannabivarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetrahydrocannabivarin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call